Trial Profile
Study of the Relationship Between the Pharmacokinetics of Vismodegib and Safety Data: a Pilot Study to Therapeutic Optimization in Patients With Basal Cell Carcinoma - OPTIVISMO-1
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer; Carcinoma
- Focus Adverse reactions
- Acronyms OPTIVISMO-1
- 17 Aug 2022 Status changed from recruiting to completed.
- 11 Jan 2021 Planned End Date changed from 1 Nov 2020 to 1 Jul 2021.
- 11 Jan 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Jul 2021.